This article has been updated to include comments from T2's earnings call.

NEW YORK (GenomeWeb) – T2 Biosystems reported after the close of the market today a more-than-five-fold increase in its first quarter revenues in part due to increased demand for its T2Candida sepsis test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.